Given the established inhibitory effects of artesunate on breast cancer, we hypothesize that its anticancer activity may be mediated through down-regulation of lncRNA TUG1, subsequent activation of miR-145-5p, and inhibition of the HOXA5/WNT signaling axis. The gene discussed is TUG1; the disease is breast cancer.